

Name of the Issue: Zota Health Care Limited

- 1 Type of issue (IPO/FPO) : Initial Public Offer (IPO) on SME Platform
- 2 Issue size (Rs crore) : Rs. 58.50 Crores
- 3 Grade of issue along with name of the rating agency : NA as the issue is being made in terms of Chapter XB of the SEBI (ICDR) Regulations, 2009
- 4 Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were arranged. : 14.83 times (after technical rejections)
- 5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Regulation 31 of the SEBI Listing Obligations & Disclosure Requirements) , 2015) : N.A
- (i) allotment in the issue : Nil
- (ii) at the end of the 1st Quarter immediately after the listing of the issue : Will be updated at the end of 1st Quarter after listing
- (iii) at the end of 1st FY : Will be updated at the end of 1st FY
- (iv) at the end of 2nd FY : Will be updated at the end of 2nd FY
- (v) at the end of 3rd FY : Will be updated at the end of 3rd FY

- 6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under Clause 41 of the listing agreement)

(Rs. in crores)

<i>Parameters</i>	<i>1st FY</i>	<i>2nd FY</i>	<i>3rd FY</i>
<i>Income from operations</i>			
<i>Net Profit for the period</i>	Will be updated at the end of 1 st FY	Will be updated at the end of 2 nd FY	Will be updated at the end of 3 rd FY
<i>Paid-up equity share capital</i>			
<i>Reserves excluding revaluation reserves</i>			

- 7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.) :
- (i) at the end of 1st FY : Will be updated at the end of 1st FY
- (ii) at the end of 2nd FY : Will be updated at the end of 2nd FY

- (iii) at the end of 3rd FY : Will be updated at the end of 3rd FY
- 8 Change, if any, in directors of issuer from the disclosures in the offer document (See Regulation 68 and Schedule III of the SEBI (Listing Obligations & Disclosure Requirements), 2015)
- (i) at the end of 1st FY : Will be updated at the end of 1st FY
- (ii) at the end of 2nd FY : Will be updated at the end of 2nd FY
- (iii) at the end of 3rd FY : Will be updated at the end of 3rd FY

- 9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements), 2015)
- Not Applicable
- (i) as disclosed in the offer document :
- (ii) Actual implementation :
- (iii) Reasons for delay in implementation, if any :

- 10 Status of utilization of issue proceeds (as submitted to stock exchanges under (as submitted to stock exchanges under Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements), 2015)

Sr. No	Particulars	Amount (Rs in Lakhs)
1.	Repayment of certain borrowings availed by company	330.00
2.	Working Capital requirements	2700.00
3.	General Corporate Purposes	809.10
	Total	3839.10

- (i) as disclosed in the offer document :
- (ii) Actual utilization : Will be updated once company files necessary disclosures with stock exchange
- (iii) Reasons for deviation, if any : Not Applicable
- 11 Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009) : Not Applicable
- 12 Price- related data : Rs. 125/-
- Issue price (Rs):

13 Basis for Issue Price and Comparison with Peer Group & Industry Average (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated):

Accounting ratio	Name of company	As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009)	At the end of 1st FY	At the end of 2nd FY	At the end of 3rd FY
EPS	Issuer (Basic and Diluted)	3.61	Will be updated at the end of 1st FY	Will be updated at the end of 2 nd FY	Will be updated at the end of 3 rd FY
	Peer Group:-				
	Gufic Biosciences Limited	0.95			
	Bal Pharma Limited	2.18			
	Jenburkt Pharmaceuticals Limited	23.18			
	Makers Laboratories Limited	4.69			
	Jagsonpal Pharmaceuticals limited	1.24			
	Alembic Limited	0.92			
P/E	Issuer	34.62			
	Peer Group:				
	Gufic Biosciences Limited	75.11			
	Bal Pharma Limited	42.00			
	Jenburkt Pharmaceuticals Limited	20.08			
	Makers Laboratories Limited	21.54			
	Jagsonpal Pharmaceuticals limited	31.53			
	Alembic Limited	42.77			
Industry Avg	NA				
RoNW (%)	Issuer	24.05%			
	Peer Group:-				
	Gufic Biosciences Limited	21.57%			
	Bal Pharma Limited	5.13%			
	Jenburkt Pharmaceuticals Limited	26.82%			
	Makers Laboratories Limited	8.76%			
	Jagsonpal Pharmaceuticals limited	3.59%			
	Alembic Limited	8.53%			
NAV per share based on	Issuer:	15.01			
	Peer Group:				
	Gufic Biosciences Limited	4.39			

Accounting ratio	Name of company	<i>As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Regulations, 2009)</i>	<i>At the end of 1st FY</i>	<i>At the end of 2nd FY</i>	<i>At the end of 3rd FY</i>
<i>balance sheet</i>	Bal Pharma Limited	42.48			
	Jenburkt Pharmaceuticals Limited	86.44			
	Makers Laboratories Limited	53.57			
	Jagsonpal Pharmaceuticals limited	34.55			
	Alembic Limited	10.84			

14 Any other material information: NA

Notes:

1. Since the shares of company were listed on January 16, 2017 we are considering March 31, 2018 as the 1st Financial Year.